Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024 - Affimed (NASDAQ:AFMD)

In 15 response-evaluable patients with metastatic EGFR wild-type NSCLC, who were pretreated with platinum doublet chemotherapy and checkpoint inhibitors, the combination of AFM24 and atezolizumab led to a disease control

Related Keywords

Seoul ,Soult Ukpyolsi ,South Korea ,Ukraine ,Chicago ,Illinois ,United States ,Germany ,Mannheim ,Baden Wüberg ,Texas ,Russia ,American ,Mary Beth Sandin ,Artiva Allo ,Hye Ryun Kim ,Andreas Harstrick ,Alexander Fudukidis ,University Of Texas Md Anderson Cancer Center ,American Society Of Clinical Oncology ,Professor At Yonsei University College Of Medicine ,American Society ,Clinical Oncology ,Chief Medical ,Chief Executive Officer ,Yonsei University College ,Developmental Therapeutics ,Cancer Center ,